In vivo dynamics and pathogenicity of wild-type and resistant Hepatitis B virus during long-term lamivudine monotherapy — a clinical note
- 14 September 2000
- journal article
- Published by Elsevier in Journal of Clinical Virology
- Vol. 17 (3) , 183-188
- https://doi.org/10.1016/s1386-6532(00)00092-5
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Quantitative Detection of Hepatitis B Virus DNA in Two International Reference Plasma PreparationsJournal of Clinical Microbiology, 1999
- Clinical impact of lamivudine resistance in chronic hepatitis BJournal of Hepatology, 1998
- Identification and characterization of mutations in hepatitis B virus resistant to lamivudineHepatology, 1998
- Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapyHepatology, 1998
- Role of Additional Mutations outside the YMDD Motif of Hepatitis B Virus Polymerase in l(−)SddC (3TC) ResistanceBiochemical Pharmacology, 1998
- Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defectiveHepatology, 1998
- Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantationThe Lancet, 1997
- A Preliminary Trial of Lamivudine for Chronic Hepatitis B InfectionNew England Journal of Medicine, 1995
- Genotypic and phenotypic characterization of HIV-1 isolated from patients receiving (−)-2′,3′-dideoxy-3′-thiacytidineAntiviral Research, 1995
- Efficacy of lamivudine on replication of hepatitis B virus in HIV-infected patientsThe Lancet, 1995